NCT03786198 is a NA clinical trial of Activity program in Early Breast Cancer, sponsored by Swiss Cancer Institute.

Who is sponsoring NCT03786198?

NCT03786198 is sponsored by Swiss Cancer Institute.

What drugs are being tested in NCT03786198?

Interventions in NCT03786198: Activity program, Control.

What condition does NCT03786198 study?

NCT03786198 studies Early Breast Cancer.

Is NCT03786198 still recruiting?

NCT03786198 is currently completed. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT03786198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Activity Program During Aromatase Inhibitor Therapy

Completed NA Last updated 27 June 2023

What this trial tests

NA trial testing Activity program in Early Breast Cancer in 375 participants. Completed in 8 June 2023.

Timeline

28 March 2019

Primary endpoint
27 September 2021

8 June 2023

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	375
Start date	28 March 2019
Primary completion	27 September 2021
Estimated completion	8 June 2023
Sites	32 locations across Switzerland

Drugs / interventions tested

Activity program
Control

Conditions studied

Early Breast Cancer — all drugs for Early Breast Cancer →

Sponsor

Swiss Cancer Institute

Who can join

18 and older, female only, with Early Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of the trial is to investigate if a simple outdoor walking intervention, which is practicable under real-life conditions, beginning at the start of adjuvant aromatase inhibitor (AI) therapy, can prevent the occurrence of muscle or joint pain/stiffness in breast cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE, Rickett K, Feng S, Vagenas D, et al · · 2020 · cited 31× · PMID 31994181 · DOI 10.1002/14651858.cd012988.pub2

Verify or expand the search:

Other recruiting trials for Early Breast Cancer

Currently open trials in the same condition.

NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT06984250 — Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer · recruiting
NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
NCT05827081 — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer · Phase 3 · recruiting

Other Swiss Cancer Institute trials

Trials by the same sponsor.

NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03786198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03786198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing